Thus, inducing upregulation of OX40 in intratumoural pDCs as well as Foxp3+ Tregs in combination with other anti-cancer treatments may enhance anti-tumour immune responses and clinical benefit. This evidence concerns the gene FOXP3 and neoplasm.